跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/EUCTR2011-003044-53-ES
EUCTR2011-003044-53-ES进行中（未招募）1 期

AN OPEN-LABEL, RANDOMISED PHASE 1B/2 STUDY OF PF-04691502 IN COMBINATION WITH LETROZOLE COMPARED WITH LETROZOLE ALONE IN PATIENTS WITH ESTROGEN RECEPTOR POSITIVE, HER-2 NEGATIVE EARLY BREAST CANCER - PF-4691502 PHASE 2 ER+ EARLY BREAST CANCER COMBINATION WITH LETROZOLE

Pfizer, S.L.U.0 个研究点目标入组 220 人开始时间: 2012年3月16日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
相关药物

试验速览

阶段
1 期
状态
进行中（未招募）
发起方
入组人数
220
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Female

入选标准

  • •1. For patients enrolled in the Phase 1B - Lead-in portion:
  • •- Postmenopausal female patients with histologically or cytologically proven diagnosis of breast cancer with evidence of metastatic disease or locally advanced disease, not amenable to resection or radiation therapy with curative intent.
  • •- ER positive and HER-2 negative breast cancer (ie, immunohistochemistry (IHC) 0 or 1+; if IHC 2+, FISH or CISH negative).
  • •- Measurable or non measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST).
  • •- Patients must be candidates to receive letrozole as standard of care.
  • •2. For patients enrolled in the Phase 2:
  • •- Postmenopausal women with newly diagnosed primary breast cancer or locally recurrent breast cancer for whom a neo-adjuvant therapy is prescribed.
  • •- ER positive and HER-2 negative breast cancer (ie, IHC 0 or 1+; if IHC 2+, FISH or CISH negative).
  • •- Tumor size >/=2 cm (as measured by ultrasound or MRI).
  • •- Ki-67 levels >10% positive cells determined by IHC at a central laboratory designated by the Sponsor.
  • •- Sufficient tumor tissue from baseline core biopsies to enable testing of biomarkers
  • •For patients enrolled in Phase 1b and Phase 2:
  • •3. ECOG Performance Status 0, or 1.
  • •4. Adequate glucose control, including no previous diagnosis of diabetes mellitus and HbA1c <7%.
  • •5. Adequate organ function as defined by the following criteria:
  • •- Absolute Neutrophil Count (ANC) >/=1,500/mm3 or >/=1.5 x 109/L.
  • •- Platelets >/=100,000/mm3 or >/=100 x 109/L.
  • •- Hemoglobin >/=9 g/dL.
  • •- Serum Aspartate Transaminase (AST) and serum Alanine Aminotransferase Transaminase (ALT) - Alkaline phosphatase - Total serum bilirubin - Serum creatinine /=60 mL/min as calculated using the method standard for the institution.
  • •6. Adequate cardiac function, including:
  • •- 12 Lead electrocardiogram (ECG) with normal tracing or non clinically significant changes that do not require medical intervention.
  • •- QTc interval 7. Resolution of all acute toxic effects of prior therapy or surgical procedures to grade 8. At least 2 weeks since any prior hormone replacement therapy or phyto oestrogens herbal alternatives, or OTC sex hormone remedies.
  • •9. Evidence of a personally signed and dated informed consent form document indicating that the patient (or legally acceptable representative) has been informed of all the pertinent aspects of the trial prior to enrollment.
  • •10. Patients who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 100
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 120

排除标准

  • •1. Patients who are investigational site staff members or patients who are Pfizer employees directly involved in the conduct of the trial.
  • •2. Clinical presentation of inflammatory carcinoma.
  • •3. (For patients enrolled in the Phase 2) Patients unwilling to undergo core biopsies after 2 and 6 weeks of treatment.
  • •4. (For patients enrolled in the Phase 1B - Lead-in portion) Presence of active brain metastases, presence of spinal cord compression, or carcinomatous meningitis, or leptomeningeal disease. Patients with previously diagnosed brain metastases are eligible if they have completed their CNS treatment and have recovered from the acute effects of radiation therapy or surgery prior to the start of study medication, have discontinued corticosteroid treatment for these metastases for at least 4 weeks and are neurologically stable.
  • •5. Prior therapy with an agent that is known or proposed to be active by action on PI3K and/or mTOR.
  • •6. Known hypersensitivity to letrozole or to any of the excipients.
  • •7. Any surgery (not including minor procedures such as lymph node biopsy, primary tumor core biopsy, fine needle aspiration) within 4 weeks of start of study treatment; or not fully recovered from any side effects of previous procedures.
  • •8. Diagnosis of any second malignancy within the last 5 years, except for adequately treated basal cell carcinoma, or squamous cell skin carcinoma, or in situ cervical carcinoma.
  • •9. Current use or anticipated need for food or drugs that are known potent CYP3A4 inhibitors.
  • •10. Current or anticipated need for food or drugs that are known potent CYP3A4 inducers.
  • •11. Concurrent administration of herbal preparations.
  • •12. Any clinically significant gastrointestinal abnormalities, which may impair intake, transit or absorption of the study drugs, such as the inability to take oral medication in tablet form and malabsorption syndrome.
  • •13. Any mental disorder that would limit the understanding or rendering of informed consent and/or compromise compliance with the requirements of this protocol.
  • •14. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and in the judgement of the investigator would make the patient inappropriate for entry into this study.
  • •15. Participation in other studies within 4 weeks before the current study begins and/or during study participation.

研究者

发起方
Pfizer, S.L.U.

相似试验

进行中（未招募）
不适用
AN OPEN-LABEL, RANDOMISED PHASE 1B/2 STUDY OF PF-04691502 IN COMBINATION WITH LETROZOLE COMPARED WITH LETROZOLE ALONE IN PATIENTS WITH ESTROGEN RECEPTOR POSITIVE, HER-2 NEGATIVE EARLY BREAST CANCERESTROGEN RECEPTOR POSITIVE, HER-2 NEGATIVE EARLY BREAST CANCER WITH KI-67 HIGHER THAN 10%MedDRA version: 15.0Level: LLTClassification code 10070575Term: Estrogen receptor positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2011-003044-53-SEPfizer Inc., 235 East 42nd Street, New York, NY 10017166
进行中（未招募）
不适用
AN OPEN-LABEL, RANDOMISED PHASE 1B/2 STUDY OF PF-04691502 IN COMBINATION WITH LETROZOLE COMPARED WITH LETROZOLE ALONE IN PATIENTS WITH ESTROGEN RECEPTOR POSITIVE, HER-2 NEGATIVE EARLY BREAST CANCER
EUCTR2011-003044-53-GBPfizer Inc., 235 East 42nd Street, New York, NY 10017166
进行中（未招募）
1 期
AN OPEN-LABEL, RANDOMISED PHASE 1B/2 STUDY OF PF-04691502 IN COMBINATION WITH LETROZOLE COMPARED WITH LETROZOLE ALONE IN PATIENTS WITH ESTROGEN RECEPTOR POSITIVE, HER-2 NEGATIVE EARLY BREAST CANCERESTROGEN RECEPTOR POSITIVE, HER-2 NEGATIVE EARLY BREAST CANCER WITH KI-67 HIGHER THAN 10%MedDRA version: 15.0Level: LLTClassification code 10070575Term: Estrogen receptor positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2011-003044-53-BEPfizer Inc., 235 East 42nd Street, New York, NY 10017166
进行中（未招募）
不适用
AN OPEN-LABEL, RANDOMISED PHASE 1B/2 STUDY OF PF-04691502 IN COMBINATION WITH LETROZOLE COMPARED WITH LETROZOLE ALONE IN PATIENTS WITH ESTROGEN RECEPTOR POSITIVE, HER-2 NEGATIVE EARLY BREAST CANCERESTROGEN RECEPTOR POSITIVE, HER-2 NEGATIVE EARLY BREAST CANCER WITH KI-67 HIGHER THAN 10% AND ESTROGEN RECEPTOR POSITIVE, HER-2 NEGATIVE ADVANCED BREAST CANCERMedDRA version: 14.1Level: LLTClassification code 10070575Term: Estrogen receptor positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2011-003044-53-DEPfizer Inc., 235 East 42nd Street, New York, NY 10017 US220
进行中（未招募）
不适用
Study to test the safety and efficacy of PF-04449913 with azacitidine versus placebo with azacitidine in patients with Intermediate-2 or high risk myelodysplastic syndrome, acute myeloid leukemia with 20-30% blasts and multi-lineage dysplasia, or chronic myelomonocytic.Intermediate-2, High-Risk Myelodysplastic Syndrome, Acute Myeloid Leukemia with 20-30% Blasts and Multi-Lineage Dysplasia, or Chronic Myelomonocytic Leukemia.MedDRA version: 18.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2014-001345-24-BEPfizer Inc. 235 East 42nd Street, New York, NY 10017170